Body Mass Index and Adverse Outcomes in Elderly Patients with Atrial Fibrillation

Stroke

Volumn 47, Issue 2, 2016, Pages 523-526

  Senoo, Keitaro ^a   Lip, Gregory Y H ^a,b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b AALBORG UNIVERSITY   (Denmark)

Author keywords

Atrial fibrillation; International normalized ratio; Mortality; Obesity; Stroke

Indexed keywords

WARFARIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; IDRAPARINUX; OLIGOSACCHARIDE;

ADVERSE OUTCOME; AGED; ANTICOAGULATION; ARTICLE; ATRIAL FIBRILLATION; BODY MASS; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COMORBIDITY; CORONARY ARTERY DISEASE; EMBOLISM; FEMALE; FRAIL ELDERLY; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; CLINICAL TRIAL; COMPLICATION; CONTROLLED STUDY; MORTALITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; OVERWEIGHT; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STATISTICAL MODEL; STROKE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; COMORBIDITY; EMBOLISM; FACTOR XA INHIBITORS; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; OBESITY; OLIGOSACCHARIDES; OVERWEIGHT; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; STROKE; WARFARIN;

EID: 84948988309     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.115.011876     Document Type: Article

References (9)

1. Wang TJ, Parise H, Levy D, D'Agostino RB Sr, Wolf PA, Vasan RS, et al. Obesity and the risk of new-onset atrial fibrillation. JAMA. 2004;292:2471-2477. doi: 10.1001/jama.292.20.2471.
2. Bousser MG, Bouthier J, Buller HR, Cohen AT, Crijns H, Davidson BL, et al. Comparison of idraparinux with vitamin k antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. Lancet. 2008;371:315-321.
3. Chiang CE, Wang KL, Lip GY. Stroke prevention in atrial fibrillation: an Asian perspective. Thromb Haemost. 2014;111:789-797. doi: 10.1160/TH13-11-0948.
4. Ardestani A, Hoffman HJ, Cooper HA. Obesity and outcomes among patients with established atrial fibrillation. Am J Cardiol. 2010;106:369-373. doi: 10.1016/j.amjcard.2010.03.036.
5. Badheka AO, Rathod A, Kizilbash MA, Garg N, Mohamad T, Afonso L, et al. Influence of obesity on outcomes in atrial fibrillation: yet another obesity paradox. Am J Med. 2010;123:646-651. doi: 10.1016/j. amjmed.2009.11.026.
6. Oreopoulos A, Padwal R, Kalantar-Zadeh K, Fonarow GC, Norris CM, McAlister FA. Body mass index and mortality in heart failure: a meta-analysis. Am Heart J. 2008;156:13-22. doi: 10.1016/j. ahj.2008.02.014.
7. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Wilson PW, et al. Impact of obesity on plasma natriuretic peptide levels. Circulation. 2004;109:594-600. doi: 10.1161/01.CIR.0000112582.16683.EA.
8. Rienstra M, Van Gelder IC, Van den Berg MP, Boomsma F, Van Veldhuisen DJ. Natriuretic peptides in patients with atrial fibrillation and advanced chronic heart failure: determinants and prognostic value of (NT-)ANP and (NT-pro)BNP. Europace. 2006;8:482-487. doi: 10.1093/europace/eul060.
9. De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease. Thromb Haemost. 2013;110:1087-1107. doi: 10.1160/TH13-06-0443.